In conclusion, our study revealed the mechanism of ANXA2/TTK/Akt/mTOR axis in the progression of ESCC, indicating that ANXA2 and TTK may serve as valuable biomarkers and therapeutic targets for ESCC. This evidence concerns the gene AKT1 and esophageal squamous cell carcinoma.